Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp. is experiencing positive momentum, with a recent increase of approximately 4% in share value, reflecting heightened investor confidence and receptiveness among key opinion leaders regarding the company's innovative therapies. The encouraging feedback highlights the clinical relevance of improvements in functional measures, particularly in the treatment of spinal muscular atrophy (SMA), where patients have shown sustained gains rather than plateauing. Additionally, the company's operational preparedness and proactive educational efforts are setting the stage for successful product uptake, further enhancing the positive outlook for its pipeline in various therapeutic areas.

Bears say

Scholar Rock Holding Corp faces a negative outlook primarily due to the postponed commercial launch of its key product, apitegromab, now pushed back significantly to 2026 for the US and 2026 for the EU, which directly impacts projected peak sales estimates. The potential for regulatory approval delays and competitive risks from advancing therapies raises concerns about the company's market position and revenue generation capabilities, making investors wary. Furthermore, while clinical experts maintain confidence in apitegromab's safety and efficacy, the overall market sentiment is clouded by uncertainties surrounding regulatory hurdles and implications for growth, leading to a downward adjustment in projections.

SRRK has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 11 analysts, SRRK has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.